NanoViricides Company Profile (NYSEMKT:NNVC)

About NanoViricides (NYSEMKT:NNVC)

NanoViricides logoNanoViricides, Inc. is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:NNVC
  • CUSIP: N/A
  • Web:
  • Market Cap: $80.1 million
  • Outstanding Shares: 63,071,000
Average Prices:
  • 50 Day Moving Avg: $1.32
  • 200 Day Moving Avg: $1.27
  • 52 Week Range: $1.03 - $1.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 31.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.35 per share
  • Price / Book: 3.63
  • EBIDTA: ($9,190,000.00)
  • Return on Equity: -60.61%
  • Return on Assets: -42.00%
  • Average Volume: 76,159 shs.
  • Beta: 0.44
  • Short Ratio: 18.99

Frequently Asked Questions for NanoViricides (NYSEMKT:NNVC)

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NNVC."

How were NanoViricides' earnings last quarter?

NanoViricides Inc (NYSEMKT:NNVC) announced its quarterly earnings data on Wednesday, February, 25th. The company reported ($0.03) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.02. The firm earned $1.82 million during the quarter, compared to analyst estimates of $1.75 million. View NanoViricides' Earnings History.

Who are some of NanoViricides' key competitors?

Who are NanoViricides' key executives?

NanoViricides' management team includes the folowing people:

  • Anil Diwan Ph.D., Chairman of the Board, President
  • Eugene Seymour M.D., Chief Executive Officer, Director
  • Meeta Vyas, Chief Financial Officer
  • Milton Boniuk, Independent Director
  • Stanley Glick CPA, Independent Director
  • Mukund S. Kulkarni Ph.D., Independent Director

How do I buy NanoViricides stock?

Shares of NanoViricides can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NanoViricides' stock price today?

One share of NanoViricides stock can currently be purchased for approximately $1.27.

MarketBeat Community Rating for NanoViricides (NYSEMKT NNVC)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NanoViricides (NYSEMKT:NNVC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NanoViricides (NYSEMKT:NNVC)
No equities research coverage for this company has been tracked by


Earnings History for NanoViricides (NYSEMKT:NNVC)
Earnings by Quarter for NanoViricides (NYSEMKT:NNVC)
Earnings History by Quarter for NanoViricides (NYSEMKT NNVC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/25/2015Q215($0.05)($0.03)$1.75 million$1.82 millionViewN/AView Earnings Details
10/2/2014($0.04)($0.07)ViewN/AView Earnings Details
5/20/2014($0.04)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NanoViricides (NYSEMKT:NNVC)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $0.04 EPS


Dividend History for NanoViricides (NYSEMKT:NNVC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NanoViricides (NYSEMKT:NNVC)
Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
Insider Trades by Quarter for NanoViricides (NYSEMKT:NNVC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/22/2015Milton BoniukDirectorBuy25,000$1.30$32,500.00View SEC Filing  
9/11/2015Milton BoniukDirectorBuy50,000$1.02$51,000.00View SEC Filing  
8/26/2015Milton BoniukDirectorBuy50,000$1.05$52,500.00View SEC Filing  
7/8/2015Milton BoniukDirectorBuy50,000$1.58$79,000.00View SEC Filing  
5/20/2015Milton BoniukDirectorBuy50,000$1.60$80,000.00View SEC Filing  
5/8/2015Milton BoniukDirectorBuy405,954$2.58$1,047,361.32View SEC Filing  
1/12/2015Anil DiwanMajor ShareholderBuy14,000$2.56$35,840.00View SEC Filing  
1/6/2015Milton BoniukDirectorBuy25,000$2.60$65,000.00View SEC Filing  
12/9/2014Milton BoniukDirectorBuy50,000$3.05$152,500.00View SEC Filing  
7/17/2014Milton BoniukDirectorBuy57,144$3.50$200,004.00View SEC Filing  
2/20/2014Anil DiwanMajor ShareholderBuy50,000$3.61$180,500.00View SEC Filing  
10/21/2013Anil DiwanMajor ShareholderSell142,000$5.29$751,180.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NanoViricides (NYSEMKT:NNVC)
Latest Headlines for NanoViricides (NYSEMKT:NNVC)
DateHeadline logoNanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on September 12, 2017 - September 12 at 6:34 AM logoNanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin - July 11 at 5:29 AM logoPioneer Trust Bank N A Buys Altria Group Inc, Automatic Data Processing Inc, Nanoviricides Inc, ... - July 8 at 1:03 PM logoNanoViricides' Poster "Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented Today at the 2017 Annual Meeting of American Society of Virology - June 27 at 6:41 AM logoNanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology - June 20 at 7:44 AM logoNanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City - June 13 at 8:57 AM logoFDA Panel To Review PTCT's Translarna, CTIC Plunges On Offering, NNVC Abuzz - June 7 at 8:35 AM logoNanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies - June 6 at 7:35 PM logoNanoViricides Files Quarterly Report for Period Ending 2017-03-31 - May 17 at 8:56 AM logoNanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 … - April 28 at 12:29 AM logoNanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles - April 26 at 6:26 PM logoNanoViricides reports 2Q loss - Yahoo Finance - February 17 at 8:27 AM logoNanoViricides Files Quarterly Report for Period Ending 2016-12-31 - February 16 at 6:24 PM logoNanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising ... - PR Newswire (press release) - February 14 at 9:44 PM logoNANOVIRICIDES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secur - February 13 at 8:03 PM logoNanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company - February 13 at 9:49 AM logoNANOVIRICIDES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - December 15 at 7:47 PM


This page was last updated on 9/22/2017 by Staff